Abstract
HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.
Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment
Current Drug Therapy
Title: Trends in the Treatment of Hepatocellular Carcinoma
Volume: 5 Issue: 2
Author(s): Janine M. Davies and Bert H. O'Neil
Affiliation:
Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment
Abstract: HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.
Export Options
About this article
Cite this article as:
M. Davies Janine and H. O'Neil Bert, Trends in the Treatment of Hepatocellular Carcinoma, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065111
DOI https://dx.doi.org/10.2174/157488510791065111 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Postpartum Depression in Women with the FMR1 Premutation
Current Psychiatry Reviews Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Estimation of Abbreviated Mycophenolic Acid Area Under the Concentration- Time Curve during Stable Post-transplant Period by Limited Sampling Strategy
Current Reviews in Clinical and Experimental Pharmacology Acylated Flavonoid Glucoside from Marrubium vulgare
Letters in Organic Chemistry Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Medicated Chewing Gum: Patient Compliance Oral Drug Delivery System
Drug Delivery Letters C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology